{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:03:23Z","timestamp":1793239403666,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T00:00:00Z","timestamp":1508112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 MH104147"],"award-info":[{"award-number":["R01 MH104147"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P01DA028555"],"award-info":[{"award-number":["P01DA028555"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 NS36126"],"award-info":[{"award-number":["R01 NS36126"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P01 NS31492"],"award-info":[{"award-number":["P01 NS31492"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["2R01 NS034239"],"award-info":[{"award-number":["2R01 NS034239"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P01 MH64570"],"award-info":[{"award-number":["P01 MH64570"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P01 NS43985"],"award-info":[{"award-number":["P01 NS43985"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30 MH062261"],"award-info":[{"award-number":["P30 MH062261"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30 AI078498"],"award-info":[{"award-number":["P30 AI078498"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 AG043540"],"award-info":[{"award-number":["R01 AG043540"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.biomaterials.2017.10.023","type":"journal-article","created":{"date-parts":[[2017,10,15]],"date-time":"2017-10-15T23:31:41Z","timestamp":1508110301000},"page":"53-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles"],"prefix":"10.1016","volume":"151","author":[{"given":"Tian","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanta","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagya Laxmi","family":"Dyavar Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Kocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Szlachetka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lamberty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard S.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Poluektova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhi","family":"Gorantla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoEllyn","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagsen","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Lee","family":"Mosley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazen","family":"Alnouti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benson","family":"Edagwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard E.","family":"Gendelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4599","key":"10.1016\/j.biomaterials.2017.10.023_bib1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barre-Sinoussi","year":"1983","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.biomaterials.2017.10.023_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/314623","article-title":"Combination antiretroviral therapy and recent declines in AIDS incidence and mortality","volume":"179","author":"Vittinghoff","year":"1999","journal-title":"J.\u00a0Infect. Dis."},{"issue":"1","key":"10.1016\/j.biomaterials.2017.10.023_bib3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/QAI.0b013e318134257a","article-title":"HIV-Infected adults with a CD4 cell count greater than 500 cells\/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population","volume":"46","author":"Lewden","year":"2007","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"issue":"3","key":"10.1016\/j.biomaterials.2017.10.023_bib4","first-page":"642","article-title":"Special contribution 2014 update of the drug resistance mutations in HIV-1","volume":"22","author":"Wensing","year":"2014","journal-title":"Top. Antivir. Med."},{"issue":"5","key":"10.1016\/j.biomaterials.2017.10.023_bib5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.coviro.2013.08.007","article-title":"Recent trends in HIV-1 drug resistance","volume":"3","author":"Siliciano","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.biomaterials.2017.10.023_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-12-296","article-title":"Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study","volume":"12","author":"Prosperi","year":"2012","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.biomaterials.2017.10.023_bib7","series-title":"Unexpectedly high rate of intolerance for dolutegravir in real life setting","author":"Berk","year":"2016"},{"issue":"4","key":"10.1016\/j.biomaterials.2017.10.023_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174613","article-title":"Socioeconomic factors explain suboptimal adherence to antiretroviral therapy among HIV-infected Australian adults with viral suppression","volume":"12","author":"Siefried","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.biomaterials.2017.10.023_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ebiom.2017.01.036","article-title":"Enhancing public health HIV interventions: a qualitative meta-synthesis and systematic review of studies to improve linkage to care, adherence, and retention","volume":"17","author":"Tucker","year":"2017","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.biomaterials.2017.10.023_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/COH.0000000000000002","article-title":"Long-acting injectable antiretrovirals for HIV treatment and prevention","volume":"8","author":"Spreen","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"4","key":"10.1016\/j.biomaterials.2017.10.023_bib11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jana.2017.03.003","article-title":"HIV stigma, retention in care, and adherence among older black women living with HIV","volume":"28","author":"Sangaramoorthy","year":"2017","journal-title":"J.\u00a0Assoc. Nurses AIDS Care"},{"issue":"1","key":"10.1016\/j.biomaterials.2017.10.023_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2989\/16085906.2016.1264983","article-title":"The multidimensional nature of HIV stigma: evidence from Mozambique","volume":"16","author":"Carrasco","year":"2017","journal-title":"Afr. J. AIDS Res."},{"issue":"11","key":"10.1016\/j.biomaterials.2017.10.023_bib13","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2217\/nnm.12.214","article-title":"Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients","volume":"8","author":"Williams","year":"2013","journal-title":"Nanomed. Lond."},{"issue":"10101","key":"10.1016\/j.biomaterials.2017.10.023_bib14","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biomaterials.2017.10.023_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0000000000000469","article-title":"GSK1265744 demonstrates robust in\u00a0vitro activity against various clades of HIV-1","volume":"68","author":"Karmon","year":"2015","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"issue":"4","key":"10.1016\/j.biomaterials.2017.10.023_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/COH.0000000000000168","article-title":"Formulation and pharmacology of long-acting cabotegravir","volume":"10","author":"Trezza","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"5","key":"10.1016\/j.biomaterials.2017.10.023_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/QAI.0000000000000301","article-title":"GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects","volume":"67","author":"Spreen","year":"2014","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"issue":"2","key":"10.1016\/j.biomaterials.2017.10.023_bib18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/00498254.2015.1060372","article-title":"Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans","volume":"46","author":"Bowers","year":"2016","journal-title":"Xenobiotica"},{"issue":"6175","key":"10.1016\/j.biomaterials.2017.10.023_bib19","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1126\/science.1248707","article-title":"Long-acting integrase inhibitor protects aacaques from intrarectal simian\/human immunodeficiency virus","volume":"343","author":"Andrews","year":"2014","journal-title":"Science"},{"issue":"270","key":"10.1016\/j.biomaterials.2017.10.023_bib20","doi-asserted-by":"crossref","first-page":"270ra4","DOI":"10.1126\/scitranslmed.3010298","article-title":"A\u00a0long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge","volume":"7","author":"Andrews","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"270","key":"10.1016\/j.biomaterials.2017.10.023_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010297","article-title":"The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge","volume":"7","author":"Radzio","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biomaterials.2017.10.023_bib22","first-page":"461","article-title":"Cabotegravir long-acting injection protects macaques against intravenous challenge with SIVmac251","author":"Andrews","year":"2016","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.biomaterials.2017.10.023_bib23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S2352-3018(17)30068-1","article-title":"Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial","volume":"4","author":"Markowitz","year":"2017","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.biomaterials.2017.10.023_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/QAI.0000000000000365","article-title":"Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults","volume":"67","author":"Spreen","year":"2014","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"issue":"10101","key":"10.1016\/j.biomaterials.2017.10.023_bib25","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0140-6736(17)31962-1","article-title":"Long-acting injectable ART: next revolution in HIV?","volume":"390","author":"Boyd","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.biomaterials.2017.10.023_bib26","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1002\/jps.23208","article-title":"An intravaginal ring for the simultaneous delivery of multiple drugs","volume":"101","author":"Baum","year":"2012","journal-title":"J.\u00a0Pharm. Sci."},{"issue":"7","key":"10.1016\/j.biomaterials.2017.10.023_bib27","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1128\/AAC.00656-15","article-title":"Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis","volume":"59","author":"Gunawardana","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biomaterials.2017.10.023_bib28","first-page":"1","article-title":"Long-acting slow effective release antiretroviral therapy","author":"Edagwa","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"issue":"3","key":"10.1016\/j.biomaterials.2017.10.023_bib29","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1172\/JCI90025","article-title":"Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs","volume":"127","author":"Gnanadhas","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"issue":"17","key":"10.1016\/j.biomaterials.2017.10.023_bib30","doi-asserted-by":"crossref","first-page":"9504","DOI":"10.1128\/JVI.01557-14","article-title":"Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance","volume":"88","author":"Guo","year":"2014","journal-title":"J.\u00a0Virol."},{"issue":"1","key":"10.1016\/j.biomaterials.2017.10.023_bib31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/aid.2014.0210","article-title":"Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates","volume":"31","author":"Freeling","year":"2015","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.biomaterials.2017.10.023_bib32","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.2147\/IJN.S68348","article-title":"Preparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue","volume":"10","author":"Roy","year":"2015","journal-title":"Int. J. Nanomed."},{"issue":"36","key":"10.1016\/j.biomaterials.2017.10.023_bib33","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.2174\/0929867321666140826114135","article-title":"Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies","volume":"21","author":"Edagwa","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biomaterials.2017.10.023_bib34","first-page":"3393","article-title":"Comparative manufacture and cell-based delivery of antiretroviral nanoformulations","volume":"6","author":"Balkundi","year":"2011","journal-title":"Int. J. Nanomed."},{"issue":"3","key":"10.1016\/j.biomaterials.2017.10.023_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/QAI.0000000000001170","article-title":"Creation of a long-acting nanoformulated 2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine","volume":"74","author":"Guo","year":"2017","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"issue":"4","key":"10.1016\/j.biomaterials.2017.10.023_bib36","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1084\/jem.167.4.1428","article-title":"Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes","volume":"167","author":"Gendelman","year":"1988","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.biomaterials.2017.10.023_bib37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12977-014-0133-5","article-title":"Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages","volume":"12","author":"Arainga","year":"2015","journal-title":"Retrovirology"},{"issue":"12","key":"10.1016\/j.biomaterials.2017.10.023_bib38","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.4049\/jimmunol.1000438","article-title":"CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice","volume":"184","author":"Gorantla","year":"2010","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.biomaterials.2017.10.023_bib39","doi-asserted-by":"crossref","first-page":"23513","DOI":"10.1038\/srep23513","article-title":"HIV-1 cellular and tissue replication patterns in infected humanized mice","volume":"6","author":"Arainga","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biomaterials.2017.10.023_bib40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.biomaterials.2014.11.012","article-title":"Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations","volume":"41","author":"Puligujja","year":"2015","journal-title":"Biomaterials"},{"issue":"33","key":"10.1016\/j.biomaterials.2017.10.023_bib41","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.0801763105","article-title":"The effect of particle design on cellular internalization pathways","volume":"105","author":"Gratton","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.biomaterials.2017.10.023_bib42","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jconrel.2010.11.019","article-title":"Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages","volume":"150","author":"Nowacek","year":"2011","journal-title":"J.\u00a0Control Release"},{"issue":"4","key":"10.1016\/j.biomaterials.2017.10.023_bib43","doi-asserted-by":"crossref","first-page":"10051","DOI":"10.1371\/journal.pone.0010051","article-title":"Macrophages recognize size and shape of their targets","volume":"5","author":"Doshi","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biomaterials.2017.10.023_bib44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nm0414-323","article-title":"Long-acting HIV drugs advanced to overcome adherence challenge","volume":"20","author":"Dolgin","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.biomaterials.2017.10.023_bib45","unstructured":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf. (Accessed 07 June 2017)."},{"key":"10.1016\/j.biomaterials.2017.10.023_bib46","doi-asserted-by":"crossref","first-page":"18911","DOI":"10.7448\/IAS.17.1.18911","article-title":"Factors associated with suboptimal adherence to antiretroviral therapy in Asia","volume":"17","author":"Jiamsakul","year":"2014","journal-title":"J.\u00a0Int. AIDS Soc."},{"issue":"1","key":"10.1016\/j.biomaterials.2017.10.023_bib47","first-page":"1","article-title":"Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts","volume":"20","author":"Bijker","year":"2017","journal-title":"J.\u00a0Int. AIDS Soc."},{"issue":"8","key":"10.1016\/j.biomaterials.2017.10.023_bib48","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S2352-3018(17)30074-7","article-title":"Long-acting cabotegravir for prevention: hope versus reality","volume":"4","author":"McCormack","year":"2017","journal-title":"Lancet HIV"},{"issue":"15","key":"10.1016\/j.biomaterials.2017.10.023_bib49","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2217\/nnm-2016-0164","article-title":"Development and characterization of a long-acting nanoformulated abacavir prodrug","volume":"11","author":"Singh","year":"2016","journal-title":"Nanomed. Lond."},{"issue":"10","key":"10.1016\/j.biomaterials.2017.10.023_bib50","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1021\/jm300492q","article-title":"Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2',3'-dideoxy-3'-thiacytidine","volume":"55","author":"Agarwal","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"issue":"43","key":"10.1016\/j.biomaterials.2017.10.023_bib51","doi-asserted-by":"crossref","first-page":"39501","DOI":"10.1074\/jbc.R100042200","article-title":"The biology and enzymology of protein N-myristoylation","volume":"276","author":"Farazi","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"issue":"32","key":"10.1016\/j.biomaterials.2017.10.023_bib52","doi-asserted-by":"crossref","first-page":"11587","DOI":"10.1073\/pnas.0404649101","article-title":"Total chemical synthesis of N-myristoylated HIV-1 matrix protein p17: structural and mechanistic implications of p17 myristoylation","volume":"101","author":"Wu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1\u20133","key":"10.1016\/j.biomaterials.2017.10.023_bib53","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0014-5793(02)03199-X","article-title":"Novel strategy for anti-HIV-1 action: selective cytotoxic effect of N-myristoyltransferase inhibitor on HIV-1-infected cells","volume":"527","author":"Takamune","year":"2002","journal-title":"FEBS Lett."},{"issue":"5","key":"10.1016\/j.biomaterials.2017.10.023_bib54","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1310\/hct1405-192","article-title":"Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor","volume":"14","author":"Spreen","year":"2013","journal-title":"HIV Clin. Trials"},{"issue":"4","key":"10.1016\/j.biomaterials.2017.10.023_bib55","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3390\/v6041837","article-title":"HIV-1 latency in monocytes\/macrophages","volume":"6","author":"Kumar","year":"2014","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.biomaterials.2017.10.023_bib56","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1084\/jem.170.4.1149","article-title":"Infection of monocyte-derived macrophages with human immunodeficiency virus type 1 (HIV-1). Monocyte-tropic and lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of cell types","volume":"170","author":"Collman","year":"1989","journal-title":"J.\u00a0Exp. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2017.10.023_bib57","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10517-011-1457-y","article-title":"Comparative analysis of esterase activities of human, mouse, and rat blood","volume":"152","author":"Rudakova","year":"2011","journal-title":"Bull. Exp. Biol. Med."},{"issue":"11","key":"10.1016\/j.biomaterials.2017.10.023_bib58","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.bcp.2005.09.002","article-title":"Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma","volume":"70","author":"Li","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biomaterials.2017.10.023_bib59","series-title":"Mouse Models for Drug Discovery: Methods and Protocols,","first-page":"105","article-title":"Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease","author":"Pino","year":"2010"},{"issue":"7588","key":"10.1016\/j.biomaterials.2017.10.023_bib60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nature16933","article-title":"Persistent HIV-1 replication maintains the tissue reservoir during therapy","volume":"530","author":"Lorenzo-Redondo","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biomaterials.2017.10.023_bib61","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/COH.0000000000000293","article-title":"Tissue reservoirs of HIV","volume":"11","author":"Wong","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"6","key":"10.1016\/j.biomaterials.2017.10.023_bib62","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1318249111","article-title":"Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues","volume":"111","author":"Fletcher","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961217306646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961217306646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T16:28:34Z","timestamp":1758904114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961217306646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":62,"alternative-id":["S0142961217306646"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2017.10.023","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2017.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}